Format

Send to

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2014 May 1;209(9):1459-68. doi: 10.1093/infdis/jit653. Epub 2013 Nov 23.

Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice.

Author information

  • 1Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee.

Abstract

Secondary bacterial pneumonia is a significant cause of morbidity and mortality during influenza, despite routine use of standard antibiotics. Antibiotic-induced immunopathology associated with bacterial cell wall lysis has been suggested to contribute to these poor outcomes. Using Streptococcus pneumoniae in a well-established murine model of secondary bacterial pneumonia (SBP) following influenza, we stratified disease severity based on pneumococcal load in the lungs via in vivo bioluminescence imaging. Ampicillin treatment cured mice with mild pneumonia but was ineffective against severely pneumonic mice, despite effective bacterial killing. Adjunctive dexamethasone therapy improved ampicillin-induced immunopathology and improved outcomes in mice with severe SBP. However, early dexamethasone therapy during primary influenza infection impaired lung adaptive immunity as manifest by increased viral titers, with an associated loss of its protective functions in SBP. These data support adjunctive clinical use of corticosteroids in severe cases of community-acquired pneumonia.

KEYWORDS:

Antibiotics; Streptococcus pneumoniae; corticosteroids; dexamethasone; immunomodulation; influenza; pneumonia

PMID:
24273183
DOI:
10.1093/infdis/jit653
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center